

Nociceptin receptor agonists - Pipeline Insight, 2022

<https://marketpublishers.com/r/N347C3F1BA42EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: N347C3F1BA42EN

Abstracts

This report can be delivered to the clients within 3-4 Business Days

DelveInsight's, "Nociceptin receptor agonists - Pipeline Insight, 2022" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Nociceptin receptor agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Nociceptin receptor agonists Understanding

Nociceptin receptor agonists: Overview

Nociceptin (also known as orphanin FQ) is a 17-amino-acid polypeptide that is structurally related to the opioid peptide dynorphin A. It is the endogenous ligand for the nociceptin opioid (NOP) receptor (formerly referred to as opioid receptor-like-1). Nociceptin does not bind to μ , κ , or δ opioid receptors, and no known exogenous or endogenous opioids bind to the NOP receptor. The neuroanatomical distribution of nociceptin and its receptor are distinct from other opioid peptides. NOP is primarily an inhibitory neuropeptide that acts on neurons to depress synaptic transmission. NOP is reported to modulate pain, stress and anxiety, feeding, learning and memory, reward and addiction, and the functioning of the heart and vessels, airways, kidney, urinary bladder, intestine, and immune cells. The broad spectrum of pharmacological effects of

NOP suggests potential therapeutic applications for NOP receptor agonists and/or antagonists.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Nociceptin receptor agonists R&D. The therapies under development are focused on novel approaches for Nociceptin receptor agonists.

Nociceptin receptor agonists Emerging Drugs Chapters

This segment of the Nociceptin receptor agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nociceptin receptor agonists Emerging Drugs

IMB-115: Imbrium Therapeutics

IMB-115 is an internally discovered compound with a novel mechanism of action in clinical development for the treatment of insomnia associated with alcohol cessation. It is a Nociceptin receptor agonist and is currently in Phase II stage of development to treat Insomnia.

Buvidal: Camurus

Buvidal is a medicine used to treat dependence on opioid (narcotic) drugs such as heroin or morphine. It is provided as weekly and monthly subcutaneous depot buprenorphine injections available in four weekly strengths (8mg, 16mg, 24mg and 32mg) and three monthly strengths (64mg, 96mg and 128mg) to allow flexible dosing according to patient's individual needs, including initiation of treatment and switching from corresponding doses of daily sublingual buprenorphine. In the EU, Buvidal is indicated for treatment of opioid dependence within a framework of medical, social and

psychological treatment, for use in adults and adolescents aged 16 years or over. Currently, it is in Phase III stage of clinical trial evaluation to treat Pain.

Further product details are provided in the report.....

Nociceptin receptor agonists: Therapeutic Assessment

This segment of the report provides insights about the different Nociceptin receptor agonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Nociceptin receptor agonists

There are approx. 12+ key companies which are developing the Nociceptin receptor agonists. The companies which have their Nociceptin receptor agonists drug candidates in the most advanced stage, i.e. Phase II include, Imbrium Therapeutics.

Phases

DelveInsight's report covers around 12+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Nociceptin receptor agonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under

various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and

Mono/Combination.

Nociceptin receptor agonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Nociceptin receptor agonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nociceptin receptor agonists drugs.

Nociceptin receptor agonists Report Insights

Nociceptin receptor agonists Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Nociceptin receptor agonists Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Nociceptin receptor agonists drugs?

How many Nociceptin receptor agonists drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nociceptin receptor agonists?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Nociceptin receptor agonists therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Nociceptin receptor agonists and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Imbrium Therapeutics

Camurus

INSYS Therapeutics

Alkermes

Aoxing Pharmaceutical Company

Tris Pharma

Chiesi Farmaceutici

Alar Pharmaceuticals

iX Biopharma

Grunenthal

Lyndra Therapeutics

Zealand Pharma

Faran Shirin

Key Products

IMB-115

Buvidal

Buprenorphine sublingual

ALKS 33-BUP

Naloxone/buprenorphine

PRK-101

ALA-1000

BnoX

Nociceptin/orphanin FQ peptide receptor agonist therapeutic

LYN-013

ZP-120

Contents

Introduction

Executive Summary

Nociceptin receptor agonists: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Nociceptin receptor agonists – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Buvidal: Camurus

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

IMB-115: Imbrium Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Buprenorphine - iX Biopharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Nociceptin receptor agonists Key Companies

Nociceptin receptor agonists Key Products

Nociceptin receptor agonists- Unmet Needs

Nociceptin receptor agonists- Market Drivers and Barriers

Nociceptin receptor agonists- Future Perspectives and Conclusion

Nociceptin receptor agonists Analyst Views

Nociceptin receptor agonists Key Companies

Appendix

I would like to order

Product name: Nociceptin receptor agonists - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/N347C3F1BA42EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N347C3F1BA42EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970